BI-CSPC@EC2611A

TRANSTHERA-B

ASIA STRAT TECH

SUMMI

MANY IDEA CLOUD

ZHONGMIAO

SKYMISSION GP

NICHE-TECH SEMI

KFM KINGDOM

INCON

CHINA CHENGTONG

01093

562050

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S

marketscreener

CSPC PHARMA

Hwabao WP CSI Pharmaceuticals ETF

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S

159316

520690

520880

513700

159570

510660

512290

159992

159837

513120

512010

159849

159892

588130

516500

CSPC Pharma Gets China Nod for Asthma Drug Trial

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai CSI Bio-medicine ETF

CSPC Innovation

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

CSPC Pharma Gets China Nod for Asthma Drug Trial

CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China

Bosera Hang Seng Health Care ETF(QDII)

CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China

CSPC Pharma Gets China Nod for Trial of Hemophilia A Drug

CSPC Pharma Gets China Nod for Trial of Hemophilia A Drug

CSPC Pharmaceutical Group has updated its board of directors, detailing roles of executive and independent non-executive directors, and clarifying the composition of its audit, nomination, and remuneration committees. This governance structure aims to enhance oversight and transparency, strengthening risk control and investor confidence in the regulated pharmaceutical sector. The latest analyst rating for CSPC stock (HK:1093) is a Hold with a price target of HK$10.70. The company has a market cap of HK$113.9B and a year-to-date price performance of 17.44%.

Tip Ranks

CSPC Pharmaceutical Updates Board Composition and Committee Roles

UBS released a research report listing investment ratings and target prices for healthcare stocks. Hengrui Pharma is rated as Buy, with the target price raised from RMB 96.9 to RMB 98.3; Hansoh Pharma is rated as Buy, with the target price raised from RMB 48.2 to RMB 51.5; Sino Biopharmaceutical is rated as Buy, with a target price of RMB 12.2; 3SBIO is rated as Buy, with a target price of RMB 41; CSPC Pharma is rated as Neutral, with the target price raised from RMB 10 to RMB 10.9; Simcere Pharma is rated as Buy, with a target price of RMB 16.3; United Lab is rated as Buy, with a target price of RMB 18.9

AASTOCKS

Dacheng CSI All Share Health Care Equipment and Services ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI HK Equities Medical and Health Integration ETF

3SBIO

Huaan Hang Seng Biotech ETF

China Universal 800 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

HANSOH PHARMA

Founder Fubon CSI Medicine and Medical Device Innovation ETF

SIMCERE PHARMA

UNITED LAB

Tianhong CNI BIOMEDICINE ETF

Hengrui Pharma

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

SINO BIOPHARM

UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)

CSPC PHARMA announced that its subsidiary, CSPC Innovation, will sell its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full media communication business platform, for a cash consideration of 230 million RMB. The estimated loss from the sale is approximately 15 million RMB

CSPC PHARMA's subsidiary sells core business for 230 million RMB

CSPC PHARMA issued a profit warning, expecting that the profit for the fiscal year 2025 will decrease by 45%-60% compared to the previous year's profit of 1.061 billion yuan. This is mainly due to the absence of large-scale epidemics domestically, coupled with medical insurance cost control leading to a decline in terminal sales of drugs, the expansion of the scope of volume-based procurement, and intensified domestic and international industry competition resulting in sustained price pressure, as well as the fact that the bromhexine hydrochloride injection will no longer be sold through the national drug procurement

"Profit Warning" CSPC PHARMA's revenue declines, expects to earn 45%-60% less for the year

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy

CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China

CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China

CSPC PHARMA's SYH2082 injection has been approved by the U.S. FDA, allowing for clinical trials in the United States. This drug is a GLP-1/GIP receptor dual biased agonist, designed to enhance efficacy and prolong action time by selectively activating the cAMP pathway. Combined with long half-life modifications and long-acting formulation technology, the goal is to achieve sustained weight loss

CSPC PHARMA's SYH2082 injection approved for clinical use in the United States

CSPC PHARMA announced that the long-acting injection of ropivacaine (SYH 9089 injection) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China. The group stated that through its long-acting drug delivery technology platform, this product can extend the duration of analgesia from a single dose to one week, and is expected to become China's first ultra-long-acting analgesic product with a duration of one week

CSPC PHARMA SYH 9089 injection approved for clinical use in China

CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials

CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SMIC

SMIC HK SDR 5to1

SJM HOLDINGS

MGM CHINA

FIT HON TENG

WUXI APPTEC

WuXi AppTec

INNOCARE

InnoCare Pharma

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

GALAXY ENT

Galaxy Entertainment Group

NAGACORP

WYNN MACAU

MELCO INT'L DEV

SANDS CHINA LTD

Sands China

INNOVENT BIO

COWELL

HUA HONG SEMI

Hua Hong

SHANGHAI FUDAN

FMSH

INNOSCIENCE

SOLOMON SYSTECH

TIGERMED

Tigermed

Apple

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

HENGRUI PHARMA

OSL GROUP

CPIC

SUNSHINE INS

CR HOLDINGS

CHINA LIFE

China Life

GUOTAI JUNAN I

AIA-R

AIA Group

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

BI-CSPC@EC2611A(26561.HK)

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S

CSPC Pharma Gets China Nod for Asthma Drug Trial

CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China

CSPC Pharma Gets China Nod for Trial of Hemophilia A Drug

CSPC Pharmaceutical Updates Board Composition and Committee Roles